2026 Q2 - tulosraportti
111 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 415 | ||
| 1 512 | ||
| 474 | ||
| 2 714 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·36 min sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/- ·4 t sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·8 t sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.
These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for 
·1 päivä sittenSome light reading material from Hansa, November: https://www.hansabiopharma.com/files/Presentations/2026/hansa-corporate-presentation-november-2026.pdf
·1 päivä sittenPersonally, I don't have any major expectations for the Q3 figures themselves. It is hardly the quarterly result that determines Hansa's future at this point. Much more interesting will be what management says about the FDA process, the preparations for a potential US launch, and what the cash position looks like going forward. With just over a month left until the FDA decision date, the Q3 result feels quite secondary. It is December that will be truly interesting. regards j
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |
2026 Q2 - tulosraportti
111 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·36 min sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/
- ·4 t sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·8 t sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for
- ·1 päivä sittenSome light reading material from Hansa, November: https://www.hansabiopharma.com/files/Presentations/2026/hansa-corporate-presentation-november-2026.pdf
- ·1 päivä sittenPersonally, I don't have any major expectations for the Q3 figures themselves. It is hardly the quarterly result that determines Hansa's future at this point. Much more interesting will be what management says about the FDA process, the preparations for a potential US launch, and what the cash position looks like going forward. With just over a month left until the FDA decision date, the Q3 result feels quite secondary. It is December that will be truly interesting. regards j
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 415 | ||
| 1 512 | ||
| 474 | ||
| 2 714 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |
2026 Q2 - tulosraportti
111 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·36 min sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/
- ·4 t sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·8 t sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for
- ·1 päivä sittenSome light reading material from Hansa, November: https://www.hansabiopharma.com/files/Presentations/2026/hansa-corporate-presentation-november-2026.pdf
- ·1 päivä sittenPersonally, I don't have any major expectations for the Q3 figures themselves. It is hardly the quarterly result that determines Hansa's future at this point. Much more interesting will be what management says about the FDA process, the preparations for a potential US launch, and what the cash position looks like going forward. With just over a month left until the FDA decision date, the Q3 result feels quite secondary. It is December that will be truly interesting. regards j
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 415 | ||
| 1 512 | ||
| 474 | ||
| 2 714 | ||
| 590 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 058 031 | 1 058 031 | 0 | 0 |